论文部分内容阅读
目的探讨血凝酶治疗脑出血早期血肿的疗效。方法将92例患者随机分为治疗组46例和对照组46例,在常规治疗基础上,治疗组给血凝酶1U静脉推注,随机1U肌内注射,对照组应用一般止血药(止血敏2g,止血芳酸0.4加液体静脉滴注),治疗前后分别进行疗效评定。结果治疗组46例中总有效率(89.13%),再出血2例(4.35%,血压均小于160/110mmHg),无消化道出血病例,死亡1例;对照组46例中3例血压均大于160/110mmHg,并发消化道出血5例,(10.87%),死亡3例;两组比较有显著差异性(P<0.05)。结论血凝酶具有良好的止血效果,有利于血肿的减少,控制再出血,不影响患者血凝功能,不会增加血栓危险,治疗脑出血早期血肿安全有效。
Objective To investigate the therapeutic effect of hemagglutinin on early hematoma of cerebral hemorrhage. Methods Ninety-two patients were randomly divided into treatment group (n = 46) and control group (n = 46). On the basis of routine treatment, the patients in the treatment group were given 1U intravenous injection of hemagglutinin and 1U were injected intramuscularly. The control group received general hemostatic 2g, hemostatic acid 0.4 plus liquid intravenous infusion), respectively, before and after treatment efficacy evaluation. Results The total effective rate (89.13%), rebleeding in 2 cases (4.35%, blood pressure less than 160 / 110mmHg) in 46 cases of treatment group, no case of gastrointestinal bleeding and 1 case of death; the blood pressure of 3 cases 160 / 110mmHg, concurrent gastrointestinal bleeding in 5 cases, (10.87%), 3 died; the two groups were significantly different (P <0.05). Conclusion Hemagglutinin has a good hemostatic effect, is conducive to the reduction of hematoma, control of rebleeding, does not affect the patient’s blood coagulation, does not increase the risk of thrombosis, the treatment of early hematoma cerebral hemorrhage safe and effective.